BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30014555)

  • 1. Panobinostat inhibits the proliferation of CD34
    Kurata T; Matsuda K; Hirabayashi K; Shigemura T; Sakashita K; Nakahata T; Koike K
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27261. PubMed ID: 30014555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
    Sakashita K; Kato I; Daifu T; Saida S; Hiramatsu H; Nishinaka Y; Ebihara Y; Ma F; Matsuda K; Saito S; Hirabayashi K; Kurata T; Uyen LT; Nakazawa Y; Tsuji K; Heike T; Nakahata T; Koike K
    Leukemia; 2015 Mar; 29(3):606-14. PubMed ID: 25102944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
    Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
    J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
    Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
    Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
    Wu Y; Zehnle PMA; Rajak J; Koleci N; Andrieux G; Gallego-Villar L; Aumann K; Boerries M; Niemeyer CM; Flotho C; Bohler S; Erlacher M
    Leukemia; 2024 Jan; 38(1):136-148. PubMed ID: 37945692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.
    Emanuel PD; Snyder RC; Wiley T; Gopurala B; Castleberry RP
    Blood; 2000 Jan; 95(2):639-45. PubMed ID: 10627474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic profiling of CD34
    Bugarin C; Antolini L; Buracchi C; Matarraz S; Coliva TA; Van der Velden VH; Szczepanski T; Da Costa ES; Van der Sluijs A; Novakova M; Mejstrikova E; Nierkens S; De Mello FV; Fernandez P; Aanei C; Sędek Ł; Strocchio L; Masetti R; Sainati L; Philippé J; Valsecchi MG; Locatelli F; Van Dongen JJM; Biondi A; Orfao A; Gaipa G
    Haematologica; 2024 Feb; 109(2):521-532. PubMed ID: 37534527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
    Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients.
    Leoncini PP; Vitullo P; Di Florio F; Tocco V; Cefalo MG; Pitisci A; Girardi K; Niemeyer C; Locatelli F; Bertaina A
    Br J Haematol; 2018 Sep; 182(6):909-912. PubMed ID: 28771681
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
    Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
    Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.
    Sun Q; So CC; Yip SF; Wan TS; Ma SK; Chan LC
    Leuk Res; 2008 Sep; 32(9):1374-81. PubMed ID: 18372040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
    Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
    Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
    Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R
    Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EVI-1 gene expression in myeloid clonogenic cells from juvenile myelomonocytic leukemia (JMML).
    Privitera E; Longoni D; Brambillasca F; Biondi A
    Leukemia; 1997 Dec; 11(12):2045-8. PubMed ID: 9447818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
    Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
    Louka E; Povinelli B; Rodriguez-Meira A; Buck G; Wen WX; Wang G; Sousos N; Ashley N; Hamblin A; Booth CAG; Roy A; Elliott N; Iskander D; de la Fuente J; Fordham N; O'Byrne S; Inglott S; Norfo R; Salio M; Thongjuea S; Rao A; Roberts I; Mead AJ
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33416891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I treat juvenile myelomonocytic leukemia.
    Locatelli F; Niemeyer CM
    Blood; 2015 Feb; 125(7):1083-90. PubMed ID: 25564399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the Evi-1 gene in haemopoietic cells of children with juvenile myelomonocytic leukaemia and normal donors.
    Gerhardt TM; Schmahl GE; Flotho C; Rath AV; Niemeyer CM
    Br J Haematol; 1997 Dec; 99(4):882-7. PubMed ID: 9432037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.